Skip to content

Study · Randomized controlled trial · n = 91 · 1995

3 results

Does desmopressin improve hemostasis and reduce blood loss from aortic surgery? A randomized, double-blind study.

Clagett GP, Valentine RJ, Myers SI, Chervu A, Heller J

Journal of vascular surgery1 Sept 1995Cited by 22 (Europe PMC)

PMID7674464 (opens in a new tab)DOI10.1016/s0741-5214(95)70134-6 (opens in a new tab)PepBankPUB-07674464
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In elective aortic operation patients, DDAVP had no beneficial effect on blood loss versus placebo.

    In plain wordsIn elective aortic operation patients, DDAVP did not improve blood loss compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    20 microgramsAs given in this study (human).

    Source sentences

    Summary
    In spite of mild prolongation in the postoperative bleeding times and moderate thrombocytopenia, DDAVP had no beneficial effect on blood loss or transfusion requirements.
    3 context sentences
    Summary · context
    The purpose of this study was to determine the effect of desmopressin acetate (DDAVP) on blood loss, transfusion requirements, and thromboembolic complications in patients undergoing elective aortic operations.
    Summary · context
    A randomized, double-blind trial was carried out during a 3-year period with patients receiving 20 micrograms DDAVP or identical-appearing placebo at the time of aortic cross-clamp placement.
    Summary · context
    Forty-three patients were randomized to receive DDAVP, and 48 were assigned to a placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In elective aortic operation patients, DDAVP had no beneficial effect on transfusion requirements versus placebo.

    In plain wordsIn elective aortic operation patients, DDAVP did not improve transfusion needs compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeTransfusion requirements
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    20 microgramsAs given in this study (human).

    Measurements

    Total blood transfusion, mean
    3.1 U
    DDAVP group
    Total blood transfusion, SD
    3 U
    DDAVP group
    Total blood transfusion, mean
    2.7 U
    placebo group
    Total blood transfusion, SD
    3 U
    placebo group

    Source sentences

    Summary
    In spite of mild prolongation in the postoperative bleeding times and moderate thrombocytopenia, DDAVP had no beneficial effect on blood loss or transfusion requirements.
    4 context sentences
    Summary · context
    Total blood transfusion amount (mean +/- standard deviation) for patients receiving DDAVP was 3.1 +/- 3.0 U compared with 2.7 +/- 3.0 U for those receiving placebo.
    Summary · context
    The purpose of this study was to determine the effect of desmopressin acetate (DDAVP) on blood loss, transfusion requirements, and thromboembolic complications in patients undergoing elective aortic operations.
    Summary · context
    A randomized, double-blind trial was carried out during a 3-year period with patients receiving 20 micrograms DDAVP or identical-appearing placebo at the time of aortic cross-clamp placement.
    Summary · context
    Forty-three patients were randomized to receive DDAVP, and 48 were assigned to a placebo.
  3. 03HumanRandomized controlled trialSafety outcome

    In elective aortic operation patients, major thromboembolic complication incidence was similar with DDAVP and placebo.

    In plain wordsIn elective aortic operation patients, major clot-related complications were similar with DDAVP and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeMajor thromboembolic complications
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    20 microgramsAs given in this study (human).

    Source sentences

    Summary
    The incidence of major thromboembolic complications was similar in both groups.
    3 context sentences
    Summary · context
    The purpose of this study was to determine the effect of desmopressin acetate (DDAVP) on blood loss, transfusion requirements, and thromboembolic complications in patients undergoing elective aortic operations.
    Summary · context
    A randomized, double-blind trial was carried out during a 3-year period with patients receiving 20 micrograms DDAVP or identical-appearing placebo at the time of aortic cross-clamp placement.
    Summary · context
    Forty-three patients were randomized to receive DDAVP, and 48 were assigned to a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.